Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports

Abstract

Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very common in checkpoint inhibitors. We present 2 cases of bullous pemphigoid, as adverse reactions to pembrolizumab-treated MM.

Keywords

• Adverse drug reaction
• Autoimmune bullous diseases
• Autoimmune diseases
• Bullous pemphigoid
• Bullous skin disease
• Malignant melanoma
• Pembrolizumab
• Programmed cell death 1
• Checkpoint inhibitors